NextCure, Inc. (NXTC): Shareholders' Equity
$34.94M
As of 2025-12-31
$12.15M
As of 2026-06-30
-40.7%
3-year compound annual growth
-34.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.94M | -46.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $65.47M | -42.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $114.42M | -31.7% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $167.53M | -28.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $233.39M | -20.5% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $293.72M | -8.6% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $321.48M | n/m | 2021-03-04, Balance as of period end |
| 2018-12-31 | -$46.94M | n/a | 2020-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $34.94M | -46.6% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $30.20M | +306.4% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $41.06M | n/m |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $7.83M | -76.1% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $35.52M | -49.5% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $28.33M | +27.4% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $39.35M | -44.9% |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗